WHO flags unethical US-backed newborn hepatitis B trial in Guinea-Bissau
The World Health Organization criticized and halted a US-funded hepatitis B vaccine trial in Guinea-Bissau that would compare vaccinating newborns at birth with delaying the dose to six weeks, calling the plan unethical and lacking justified scientific safeguards; the birth dose is a proven public health intervention, and about 14,000 babies were to be enrolled before the government suspended the project amid public outrage. Guinea-Bissau plans to roll out the birth-dose nationwide by 2028, with WHO support to accelerate adoption.